Analystreport

Millendo Therapeutics Inc (NASDAQ: MLND) had its "buy" rating re-affirmed by analysts at Roth Capital. They now have a $6.00 price target on the stock.

Millendo Therapeutics, Inc. - Common Stock  (MLND) 
Last millendo therapeutics, inc. - common stock earnings: 11/13 08:30 am Check Earnings Report